BioLineRx Reports Q2 GAAP EPS of $0.00 and Revenue of $0.3M
BioLineRx (NASDAQ: BLRX) reported second-quarter results with a GAAP earnings per share (EPS) of $0.00, in line with market expectations. The company generated revenue of $0.3 million for the quarter, representing a year-over-year increase of 3.4%. As of June 30, BioLineRx held $13.1 million on its balance sheet and confirmed it maintains sufficient cash to fund operations through at least mid-2027. The company is also planning a direct offering targeting $3.75 million in proceeds, which will include new American Depositary Shares (ADS) with warrants attached. This move suggests BioLineRx aims to strengthen its financial position ahead of potential clinical or operational milestones.
Tickers: $BLRX
Topics: capital_raise cash_position financials